Compare AL & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AL | GRFS |
|---|---|---|
| Founded | 2010 | 1940 |
| Country | United States | Spain |
| Employees | 160 | 25247 |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 5.8B |
| IPO Year | N/A | N/A |
| Metric | AL | GRFS |
|---|---|---|
| Price | $64.63 | $7.99 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $66.67 | $10.15 |
| AVG Volume (30 Days) | ★ 2.1M | 647.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | 1.36% | ★ 1.77% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.98 | $5.33 |
| Revenue Next Year | $5.32 | $6.50 |
| P/E Ratio | ★ $6.97 | $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $38.25 | $6.19 |
| 52 Week High | $64.97 | $11.14 |
| Indicator | AL | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 48.23 | 29.52 |
| Support Level | $63.44 | $7.64 |
| Resistance Level | $64.97 | $9.85 |
| Average True Range (ATR) | 0.13 | 0.30 |
| MACD | -0.03 | -0.12 |
| Stochastic Oscillator | 25.56 | 8.19 |
Air Lease Corp is an aircraft leasing company based in the United States. It is engaged in the modern, fuel-efficient new technology commercial jet aircraft directly from aircraft manufacturers and leasing those aircraft to airlines throughout the world to generate attractive returns on equity. The company also sells aircraft from its fleet to third parties, including other leasing companies, financial services companies, airlines, and other investors, and offers fleet management services to investors and owners of aircraft portfolios for a management fee. Geographically, it derives a maximum of its revenue from the Europe and the rest from Asia Pacific, Middle East and Africa, Central America, South America, Mexico, the United States, and Canada.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.